The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ...
Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...
DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...
8 analysts have shared their evaluations of DexCom (NASDAQ:DXCM) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results